GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioVie Inc (NAS:BIVI) » Definitions » Gross Margin %

BIVI (BioVie) Gross Margin % : 0.00% (As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is BioVie Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. BioVie's Gross Profit for the three months ended in Sep. 2024 was $0.00 Mil. BioVie's Revenue for the three months ended in Sep. 2024 was $0.00 Mil. Therefore, BioVie's Gross Margin % for the quarter that ended in Sep. 2024 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.


The historical rank and industry rank for BioVie's Gross Margin % or its related term are showing as below:


BIVI's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 60.58
* Ranked among companies with meaningful Gross Margin % only.

BioVie had a gross margin of N/A% for the quarter that ended in Sep. 2024 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for BioVie was 0.00% per year.


BioVie Gross Margin % Historical Data

The historical data trend for BioVie's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioVie Gross Margin % Chart

BioVie Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BioVie Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BioVie's Gross Margin %

For the Biotechnology subindustry, BioVie's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioVie's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioVie's Gross Margin % distribution charts can be found below:

* The bar in red indicates where BioVie's Gross Margin % falls into.



BioVie Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

BioVie's Gross Margin for the fiscal year that ended in Jun. 2024 is calculated as

Gross Margin % (A: Jun. 2024 )=Gross Profit (A: Jun. 2024 ) / Revenue (A: Jun. 2024 )
=0 / 0
=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 0) / 0
=N/A %

BioVie's Gross Margin for the quarter that ended in Sep. 2024 is calculated as


Gross Margin % (Q: Sep. 2024 )=Gross Profit (Q: Sep. 2024 ) / Revenue (Q: Sep. 2024 )
=0 / 0
=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 0) / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


BioVie  (NAS:BIVI) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

BioVie had a gross margin of N/A% for the quarter that ended in Sep. 2024 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


BioVie Gross Margin % Related Terms

Thank you for viewing the detailed overview of BioVie's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


BioVie Business Description

Traded in Other Exchanges
N/A
Address
680 W Nye Lane, Suite 204, Carson, NV, USA, 89703
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
Executives
Steve Gorlin director 150 GULF SHORE DRIVE, UNIT 601, DESTIN FL 32541
Cuong V Do director C/O BIOVIE, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Richard J Berman director 305 COLLEGE ROAD EAST, PRINCETON NJ 08540
James Paul Lang director C/O BIOVIE, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Michael Edward Sherman director C/O BIOVIE, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Robert J Hariri director 341 MENDHAM ROAD, BERNARDSVILLE NJ 07924
Joanne Wendy Kim officer: Chief Financial Officer C/O BIOVIE, INC, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Joseph M Palumbo other: Chief Medical Officer 616 BROOKSIDE AVENUE, SAINT DAVIDS PA 19087
Jonathan M Adams officer: EVP Liver Cirrhosis Programs 100 CUMMINGS CENTER 247C, BEVERLY MA 01915
Penelope Markham officer: EVP Liver Cirrhosis R&D C/O BIOVIE, INC, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Christopher Reading officer: EVP Neuroscience R&D C/O HOLLIS-EDEN PHARMACEUTICALS, 4435 EASTGATE MALL STE.400, SAN DIEGO CA 92121
Clarence N. Ahlem officer: EVP of Product Development 5305 RENAISSANCE AVE., SAN DIEGO CA 92122
Mina Sooch director 17199 N. LAUREL PARK DRIVE, SUITE 401, LIVONIA MI 48152
Sigmund Rogich director C/O BIOVIE, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Patrick D Yeramian officer: Chief Medical Officer 1815 PARKSIDE CIRCLE SOUTH, BOCA RATON FL 33486